New cocktail of Liver-Directed chemo and immunotherapy targets deadly bile duct cancer
NCT ID NCT07646717
First seen Jun 24, 2026
Summary
This phase 2 trial tests a combination of liver-directed chemotherapy (irinotecan liposome plus 5-FU/LV) with targeted therapy (lenvatinib) and immunotherapy (PD-1 inhibitors) as a first treatment for advanced intrahepatic cholangiocarcinoma, a rare and aggressive bile duct cancer. The study enrolls 30 adults with unresectable or metastatic disease. The goal is to see if this approach can shrink tumors and improve outcomes, while monitoring side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA (ICC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
irinotecan liposome, 5-FU/LV, lenvatinib, and PD-1 inhibitors
What this could lead to
If successful, this combination could offer a new first-line treatment option to shrink tumors and improve survival for people with advanced bile duct cancer.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The combination therapy also carries risks of serious side effects from chemotherapy, targeted therapy, and immunotherapy.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.